153 related articles for article (PubMed ID: 30823852)
1. Impact of dosing frequency (once daily or twice daily) on patient adherence to oral targeted therapies for hematologic malignancies: a retrospective cohort study among managed care enrollees.
Patel K; Sudhir VS; Kabadi S; Huang JC; Porwal S; Thakkar K; Pagel JM
J Oncol Pharm Pract; 2019 Dec; 25(8):1897-1906. PubMed ID: 30823852
[TBL] [Abstract][Full Text] [Related]
2. Medication Adherence, Health Care Utilization, and Costs Among Patients Initiating Oral Oncolytics for Multiple Myeloma or Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Dashputre AA; Gatwood KS; Gatwood J
J Manag Care Spec Pharm; 2020 Feb; 26(2):186-196. PubMed ID: 32011965
[TBL] [Abstract][Full Text] [Related]
3. Impact of daily dosing frequency on adherence to chronic medications among nonvalvular atrial fibrillation patients.
Laliberté F; Nelson WW; Lefebvre P; Schein JR; Rondeau-Leclaire J; Duh MS
Adv Ther; 2012 Aug; 29(8):675-90. PubMed ID: 22898791
[TBL] [Abstract][Full Text] [Related]
4. Impact of once-daily versus twice-daily dosing frequency on adherence to chronic medications among patients with venous thromboembolism.
Laliberté F; Bookhart BK; Nelson WW; Lefebvre P; Schein JR; Rondeau-Leclaire J; Duh MS
Patient; 2013; 6(3):213-24. PubMed ID: 23857628
[TBL] [Abstract][Full Text] [Related]
5. Retrospective real-world adherence in patients with type 2 diabetes initiating once-daily liraglutide 1.8 mg or twice-daily exenatide 10 μg.
Malmenäs M; Bouchard JR; Langer J
Clin Ther; 2013 Jun; 35(6):795-807. PubMed ID: 23642290
[TBL] [Abstract][Full Text] [Related]
6. Oral antidiabetic therapy in a large Italian sample: drug supply and compliance for different therapeutic regimens.
Vittorino Gaddi A; Benedetto D; Capello F; Di Pietro C; Cinconze E; Rossi E; De Sando V; Cevenini M; D'Alò G
Public Health; 2014 Jan; 128(1):70-6. PubMed ID: 23969148
[TBL] [Abstract][Full Text] [Related]
7. Adherence and dosing frequency of common medications for cardiovascular patients.
Bae JP; Dobesh PP; Klepser DG; Anderson JD; Zagar AJ; McCollam PL; Tomlin ME
Am J Manag Care; 2012 Mar; 18(3):139-46. PubMed ID: 22435907
[TBL] [Abstract][Full Text] [Related]
8. Adherence and persistence to urate-lowering therapies in the Irish setting.
McGowan B; Bennett K; Silke C; Whelan B
Clin Rheumatol; 2016 Mar; 35(3):715-21. PubMed ID: 25409858
[TBL] [Abstract][Full Text] [Related]
9. A retrospective study of persistence, adherence, and health economic outcomes of fixed-dose combination vs. loose-dose combination of oral anti-diabetes drugs.
Lokhandwala T; Smith N; Sternhufvud C; Sörstadius E; Lee WC; Mukherjee J
J Med Econ; 2016; 19(3):203-12. PubMed ID: 26473990
[TBL] [Abstract][Full Text] [Related]
10. Treatment adherence in newly diagnosed type 2 diabetes: patient characteristics and long-term impact of adherence on inpatient care utilization.
Sun P; Lian J
Postgrad Med; 2016 May; 128(4):338-45. PubMed ID: 26849064
[TBL] [Abstract][Full Text] [Related]
11. Systematic Literature Review and Meta-analysis of Medication Adherence With Once-weekly Versus Once-daily Therapy.
Iglay K; Cao X; Mavros P; Joshi K; Yu S; Tunceli K
Clin Ther; 2015 Aug; 37(8):1813-21.e1. PubMed ID: 26117406
[TBL] [Abstract][Full Text] [Related]
12. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis.
Cramer JA; Amonkar MM; Hebborn A; Altman R
Curr Med Res Opin; 2005 Sep; 21(9):1453-60. PubMed ID: 16197664
[TBL] [Abstract][Full Text] [Related]
13. Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice.
Chapple CR; Nazir J; Hakimi Z; Bowditch S; Fatoye F; Guelfucci F; Khemiri A; Siddiqui E; Wagg A
Eur Urol; 2017 Sep; 72(3):389-399. PubMed ID: 28196724
[TBL] [Abstract][Full Text] [Related]
14. Persistence with and adherence to fingolimod compared with other disease-modifying therapies for the treatment of multiple sclerosis: a retrospective US claims database analysis.
Bergvall N; Petrilla AA; Karkare SU; Lahoz R; Agashivala N; Pradhan A; Capkun G; Makin C; McGuiness CB; Korn JR
J Med Econ; 2014 Oct; 17(10):696-707. PubMed ID: 25019581
[TBL] [Abstract][Full Text] [Related]
15. Adherence and Persistence Across Antidepressant Therapeutic Classes: A Retrospective Claims Analysis Among Insured US Patients with Major Depressive Disorder (MDD).
Keyloun KR; Hansen RN; Hepp Z; Gillard P; Thase ME; Devine EB
CNS Drugs; 2017 May; 31(5):421-432. PubMed ID: 28378157
[TBL] [Abstract][Full Text] [Related]
16. Adherence, persistence, and inpatient utilization among adult schizophrenia patients using once-monthly versus twice-monthly long-acting atypical antipsychotics.
Pilon D; Alcusky M; Xiao Y; Thompson-Leduc P; Lafeuille MH; Lefebvre P; Benson C
J Med Econ; 2018 Feb; 21(2):135-143. PubMed ID: 28895766
[TBL] [Abstract][Full Text] [Related]
17. Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) Therapy Adherence for Patients with Type 2 Diabetes in a Medicare Population.
Nguyen H; Dufour R; Caldwell-Tarr A
Adv Ther; 2017 Mar; 34(3):658-673. PubMed ID: 28078541
[TBL] [Abstract][Full Text] [Related]
18. Adherence to oral antidiabetic medications in the pediatric population with type 2 diabetes: a retrospective database analysis.
Adeyemi AO; Rascati KL; Lawson KA; Strassels SA
Clin Ther; 2012 Mar; 34(3):712-9. PubMed ID: 22381712
[TBL] [Abstract][Full Text] [Related]
19. Adherence with pharmacotherapy for type 2 diabetes: a retrospective cohort study of adults with employer-sponsored health insurance.
Hertz RP; Unger AN; Lustik MB
Clin Ther; 2005 Jul; 27(7):1064-73. PubMed ID: 16154485
[TBL] [Abstract][Full Text] [Related]
20. Predictors of non-adherence to systemic oral therapy for advanced hepatocellular carcinoma.
Mallick R; Cai J; Wogen J
Curr Med Res Opin; 2013 Dec; 29(12):1701-8. PubMed ID: 24010684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
